OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
45
Results
Show all
Save search
Copy query
Show results for
Unknown
(45)
Release Date
2024
(11)
2023
(7)
2022
(6)
2020
(4)
2025
(3)
2021
(3)
2016
(3)
2014
(3)
2019
(1)
2018
(1)
2015
(1)
2013
(1)
2011
(1)
Previous
page
1 / 5
You're on page
1
page
2
page
3
page
4
page
5
Next
page
Sort
by:
Relevance
Page size
10
Vimentin intermediate filaments and filamentous actin form unexpected interpenetrating networks that redefine the cell cortex.
Not available
S-EPMC8915831
|
biostudies-literature
Cite
Smoking Cessation and Incident Cardiovascular Disease.
Not available
S-EPMC11530932
|
biostudies-literature
Cite
Time to Treat First Acute Attack of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.
Not available
S-EPMC11372657
|
biostudies-literature
Cite
Differentiated pattern of complement system activation between MOG-IgG-associated disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder.
Not available
S-EPMC10991751
|
biostudies-literature
Cite
Surgery and proton radiation therapy for pediatric base of skull chordomas: Long-term clinical outcomes for 204 patients.
Not available
S-EPMC10484173
|
biostudies-literature
Cite
An epigenomic roadmap to induced pluripotency reveals DNA methylation as a reprogramming modulator.
Not available
S-EPMC4284806
|
biostudies-literature
Cite
Genome sequencing reveals novel noncoding variants in PLA2G6 and LMNB1 causing progressive neurologic disease.
Not available
S-EPMC9000935
|
biostudies-literature
Cite
Sex-related differences in presentation, treatment, and outcomes of Asian patients with atrial fibrillation: a report from the prospective APHRS-AF Registry.
Not available
S-EPMC10603128
|
biostudies-literature
Cite
Validating the predictive ability of the 2MACE score for major adverse cardiovascular events in patients with atrial fibrillation: results from phase II/III of the GLORIA-AF registry.
Not available
S-EPMC10830583
|
biostudies-literature
Cite
Switching treatment to cipaglucosidase alfa plus miglustat positively affects patient-reported outcome measures in patients with late-onset Pompe disease.
Not available
S-EPMC11561219
|
biostudies-literature
Cite
Previous
page
1 / 5
You're on page
1
page
2
page
3
page
4
page
5
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets